Ancillary Testing for the Diagnosis of Pancreatic Ductal Adenocarcinoma

  • David C. Chhieng
  • Edward B. Stelow
Part of the Essentials in Cytopathology book series (EICP, volume 3)


Over the last decade, the molecular biology of pancreatic ductal adenocarcinoma (PDA) has been, the subject of intense investigation. As a result, our understanding of the pathogenesis of PDA has significantly advanced. This chapter discusses some of these advances and how they and other developments have facilitated ancillary testing of cytologic samples for the diagnosis of PDA.


Pancreatic Ductal Adenocarcinoma Intraductal Papillary Mucinous Neoplasm Prostate Stem Cell Antigen Ancillary Test Pancreatic Ductal Carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Chhieng DC, Benson E, Eltoum I, et al. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer 2003;99:365–371.PubMedCrossRefGoogle Scholar
  2. Giorgadze TA, Peterman H, Baloch ZW, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation. Cancer 2006;108:186–197.PubMedCrossRefGoogle Scholar
  3. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006;126:572–579.PubMedCrossRefGoogle Scholar
  4. Lapkus O, Gologan O, Liu Y, et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol 2006;19:907–913.PubMedCrossRefGoogle Scholar
  5. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902–912.PubMedCrossRefGoogle Scholar
  6. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11:238–243.PubMedGoogle Scholar
  7. Saxby AJ, Nielsen A, Scarlett CJ, et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005;29:1125–1133.PubMedCrossRefGoogle Scholar
  8. Tada M, Komatsu Y, Kawabe T, et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002;97:2263–2270.PubMedCrossRefGoogle Scholar
  9. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol 2000;156:1641–1651.PubMedCrossRefGoogle Scholar
  10. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002;117:755–765.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • David C. Chhieng
    • 1
  • Edward B. Stelow
    • 2
  1. 1.Department of PathologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of PathologyUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations